EP4739307A2 - Zielgerichtete epigenetische therapien für störungen des progranulinmangels - Google Patents

Zielgerichtete epigenetische therapien für störungen des progranulinmangels

Info

Publication number
EP4739307A2
EP4739307A2 EP24836549.6A EP24836549A EP4739307A2 EP 4739307 A2 EP4739307 A2 EP 4739307A2 EP 24836549 A EP24836549 A EP 24836549A EP 4739307 A2 EP4739307 A2 EP 4739307A2
Authority
EP
European Patent Office
Prior art keywords
compound
mmol
alkyl
pyridin
pgrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24836549.6A
Other languages
English (en)
French (fr)
Inventor
Stephen J. Haggarty
Zachary ROSENTHAL
Ralph Mazitschek
Debasis Patnaik
Neil Payne
Jacob M. HOOKER
Michael PACZEK
Daniel M. FASS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP4739307A2 publication Critical patent/EP4739307A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24836549.6A 2023-07-03 2024-07-02 Zielgerichtete epigenetische therapien für störungen des progranulinmangels Pending EP4739307A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363524837P 2023-07-03 2023-07-03
US202363610275P 2023-12-14 2023-12-14
PCT/US2024/036596 WO2025010291A2 (en) 2023-07-03 2024-07-02 Targeted epigenetic therapies for disorders of progranulin deficiency

Publications (1)

Publication Number Publication Date
EP4739307A2 true EP4739307A2 (de) 2026-05-13

Family

ID=94172190

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24836549.6A Pending EP4739307A2 (de) 2023-07-03 2024-07-02 Zielgerichtete epigenetische therapien für störungen des progranulinmangels

Country Status (2)

Country Link
EP (1) EP4739307A2 (de)
WO (1) WO2025010291A2 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005307718A1 (en) * 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids for the treatment of diabetes
WO2011156626A1 (en) * 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2012225805B2 (en) * 2011-03-04 2017-03-02 Lexicon Pharmaceuticals, Inc. MST1 kinase inhibitors and methods of their use
DK3290407T3 (da) * 2013-10-18 2020-03-23 Celgene Quanticel Res Inc Bromodomæneinhibitorer
CN107735396B (zh) * 2015-07-01 2021-03-02 先正达参股股份有限公司 具有含硫取代基的杀有害生物活性多环衍生物
WO2018195155A1 (en) * 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
WO2025010291A3 (en) 2025-05-01
WO2025010291A2 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
ES2963590T3 (es) Inhibidor de EZH2 y uso del mismo
CN110420327B (zh) 人ezh2抑制剂及其应用方法
EP2989103B1 (de) N-acyl-(3-substituierte)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine als selektive nk-3-rezeptor-antagonisten, pharmazeutische zusammensetzung, verfahren zur verwendung in nk-3-rezeptorvermittelten erkrankungen
US20180243315A1 (en) Inhibitors of human ezh2, and methods of use thereof
US12398127B2 (en) Thyroid hormone receptor beta agonist compounds
WO2018136202A2 (en) Compounds and methods for cdk8 modulation and indications therefor
EP4534533A1 (de) Azachinolinonderivat, herstellungsverfahren dafür und verwendung davon
JP5775094B2 (ja) 統合失調症の処置に有用な選択的ｍＧｌｕ５受容体増強因子としてのテトラヒドロトリアゾロピリジン化合物
US20180354946A1 (en) Compounds and methods for kinase modulation
US10226461B2 (en) Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US12084419B2 (en) Cell metabolism modulating compounds and uses thereof
US20160326172A1 (en) New compounds
TW201625610A (zh) 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物
WO2021202900A1 (en) 1,6-naphthyridine compounds and methods for csk modulation and indications therefor
EP3459948A1 (de) Fluorhaltiges triazolopyridin und herstellungsverfahren, pharmazeutische zusammensetzung und anwendung davon
EP3194389B1 (de) Vom imidazo[4,5-c]pyridin abgeleitete ssao inhibitoren
US20110212031A1 (en) Novel substituted azabenzoxazoles
WO2025010291A2 (en) Targeted epigenetic therapies for disorders of progranulin deficiency
JP2021519825A (ja) 輸送体の調節薬としての二環式エノンカルボキシラートとその使用
TWI564300B (zh) 經取代之［（５Ｈ－吡咯［２，１－ｃ］［１，４］苯二氮呯－１１－基）哌嗪－１－基］－２，２－二甲基丙酸化合物作為雙重活性Ｈ１反向促進劑／５－ＨＴ2Ａ拮抗劑
JP2021505639A (ja) ２−オキソ−１−ピロリジニルイミダゾチアジアゾール誘導体
RU2826177C1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
US20250241905A1 (en) 3-beta-hsd1 inhibitors and compositions and uses thereof
WO2025085527A1 (en) 3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
JP2020526532A (ja) ２−オキソ−１，３−オキサゾリジニルイミダゾチアジアゾール誘導体

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260129

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR